SCHEMBL8291387

SCHEMBL8291387

CC(=N)c1ccc2ccccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.63
PLG P00747 1/20 0.63
PLAU P00749 1/20 0.63
KLKB1 P03952 1/20 0.63
KLK1 P06870 1/20 0.63
PRSS1 P07477 1/20 0.63
CES2 O00748 1/20 0.56
CES1 P23141 1/20 0.56
HPGD P15428 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
EGFR P00533 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21206956 0.92 PLAU (0.55) F2PLGPLAUKLKB1KLK1
SCHEMBL397225 0.81 CES2 (0.60) F2PLGPLAUKLKB1KLK1
SCHEMBL23890384 0.80 HPGD (0.58) F2PLGPLAUKLKB1KLK1
SCHEMBL21206942 0.78 ESR1 (0.50) F2PLGPLAUKLKB1KLK1
SCHEMBL43058 0.77 ALDH1A1 (0.71) F2PLGPLAUKLKB1KLK1
SCHEMBL3399368 0.77 F2 (0.63) F2PLGPLAUKLKB1KLK1
SCHEMBL30999689 0.77 CES2 (0.56) F2PLGPLAUKLKB1KLK1
SCHEMBL3370031 0.77 PLAU (1.00) F2PLGPLAUKLKB1KLK1
SCHEMBL29521283 0.77 CES2 (0.56) F2PLGPLAUKLKB1KLK1
SCHEMBL29941688 0.77 PLAU (1.00) F2PLGPLAUKLKB1KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355705-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS THE UNIVERSITY OF HONG KONG (CN) 2023-11-09 US disclosed
US-11370740-B2 Method for producing ester group-containing compound DIC CORPORATION (JP) 2022-06-28 US disclosed
US-10919870-B2 Polymerizable compound and optically anisotropic body DIC CORPORATION (JP) 2021-02-16 US disclosed
US-20200199453-A1 POLYMERISABLE LIQUID CRYSTAL MATERIAL AND POLYMERISED LIQUID CRYSTAL FILM MERCK PATENT GMBH (DE) 2020-06-25 US disclosed
EP-2892525-B1 METHODS OF TREATING MUSCULAR DYSTROPHY UNIV NEVADA RENO (US) 2018-06-13 EP disclosed
EP-2788359-B1 COMPOSITION AND METHOD FOR NEUROPEPTIDE S RECEPTOR (NPSR) ANTAGONISTS RES TRIANGLE INST (US) 2017-03-01 EP disclosed
EP-1636218-B1 THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS MERCK PATENT GMBH (DE) 2009-03-25 EP disclosed
WO-2005037779-A2 NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES IMTM GMBH (DE) 2005-04-28 WO disclosed
WO-2005037257-A2 NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES IMTM GMBH (DE) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11370740-B2 Method for producing ester group-containing compound COASY, TAF5, TAF9 F2 345/4885PLG 2742/4885PLAU 3316/4885
US-10919870-B2 Polymerizable compound and optically anisotropic body ZYX, ZW10, DPY30 F2 308/4885PLG 370/4885PLAU 502/4885
US-20230355705-A1 DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS YEATS2, YEATS4, KNTC1 F2 4877/4885PLG 4148/4885PLAU 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.